HSP90AB1 and head and neck squamous cell carcinoma: One study revealed that low, nontoxic doses of the Hsp90 inhibitor AT13387 (Onalespib) can selectively sensitize head and neck squamous cell carcinoma (HNSCC) and pancreatic cancer cells to radiotherapy, while there was no synergetic effect on normal cells [93].